2361493-16-3 Usage
Uses
Used in Pharmaceutical Industry:
N-(2-(2-(2-(2-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide is used as a potential pharmaceutical agent for its diverse pharmacological properties due to its complex molecular structure. N-(2-(2-(2-(2-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide's specific applications would need to be determined through further research and clinical trials.
Used in Chemical Research:
In the field of chemical research, N-(2-(2-(2-(2-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide serves as a subject for studying the synthesis and modification of complex organic molecules. Its unique structure may provide insights into the development of new synthetic pathways and the exploration of novel chemical reactions.
Used in Drug Discovery:
N-(2-(2-(2-(2-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide is used in drug discovery for its potential as a lead compound in the development of new therapeutic agents. Its complex structure may offer multiple points of interaction with biological targets, making it a promising candidate for further optimization and development.
Check Digit Verification of cas no
The CAS Registry Mumber 2361493-16-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,3,6,1,4,9 and 3 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 2361493-16:
(9*2)+(8*3)+(7*6)+(6*1)+(5*4)+(4*9)+(3*3)+(2*1)+(1*6)=163
163 % 10 = 3
So 2361493-16-3 is a valid CAS Registry Number.
2361493-16-3Relevant academic research and scientific papers
COMPOUND FOR INHIBITING AND DEGRADING CDK
-
Paragraph 0146; 0149-0150; 0155; 0160; 0162, (2020/07/23)
The present invention provides is a compound for inhibiting and degrading CDK. Specifically the present invention provides a compound represented by formula I, definitions of radical groups being described in the specification. The compound in the present invention has a very good inhibitory activity for the cyclin-dependent kinase (CDK), and can be used in the preparation of drugs for treating diseases related to the activity of the CDK.
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML
Brand, Matthias,Jiang, Baishan,Bauer, Sophie,Donovan, Katherine A.,Liang, Yanke,Wang, Eric S.,Nowak, Rados?aw P.,Yuan, Jingting C.,Zhang, Tinghu,Kwiatkowski, Nicholas,Müller, André C.,Fischer, Eric S.,Gray, Nathanael S.,Winter, Georg E.
, p. 300 - 9,306 (2019/02/19)
The design of selective small molecules is often stymied by similar ligand binding pockets. Here, we report BSJ-03-123, a phthalimide-based degrader that exploits protein-interface determinants to achieve proteome-wide selectivity for the degradation of cyclin-dependent kinase 6 (CDK6). Pharmacologic CDK6 degradation targets a selective dependency of acute myeloid leukemia cells, and transcriptomics and phosphoproteomics profiling of acute degradation of CDK6 enabled dynamic mapping of its immediate role in coordinating signaling and transcription. Brand et al. describe BSJ-03-123, a degrader with proteome-wide selectivity for CDK6. Specificity emerges from differential ternary complex formation with the E3 ligase CRL4CRBN. BSJ-03-123 exploits a dependency of AML cells on CDK6, and rapid degradation allowed assaying the role of CDK6 in coordinating signaling and gene control in AML.
